ReQuip

REQUIP CLASS ACTION CERTIFIED - NEGOTIATION PROCESS AGREED TO BETWEEN THE PARTIES

We are pleased to announce the Certification of the ReQup class action by Order of the Honourable Justice Lax dated October 22, 2013.

To review the official Certification Notice please click here.

We are also pleased to announce the agreement between the parties to develop a Negotiation Process aimed at determining whether the claims of Class Members can potentially be resolved without further litigation.

If you are a person resident in Canada (other than Quebec) who was prescribed the drug ReQuip (generic name Ropinirole Hydrochloride) in Canada and ingested the drug ReQuip at any time on or before October 22, 2013 and claim, as a result, to have suffered damages relating to an impulse control disorder (such as pathological gambling, hyper-sexuality, compulsive shopping and/or binge eating) we strongly encourage you to participate in the Negotiation Process. 

To participate in the Negotiation Process, you must submit a completed Negotiation Process Questionnaire to Thomson, Rogers, by no later than, January 31, 2014.

Below you will find the following important documents:

  1. Order of Justice Lax dated October 22, 2013
  2. Certification Notice
  3. Negotiation Process Questionnaire

If you intend to participate in the Negotiation Process and have not already been in contact with us at Thomson, Rogers please contact us at 1-888-223-0448 for further information.

 

******************************************************************************************
UPDATE: OCTOBER 2, 2013
******************************************************************************************

The Certification Motion has been adjourned until October 22, 2013. We will update the website afterwards.

 

******************************************************************************************
UPDATE: JULY 3, 2013
******************************************************************************************
This action is proceeding to a Certification Motion on September 11th, 2013. More details regarding the Certification Motion will follow shortly.
******************************************************************************************

 

On November 20, 2009, THOMSON, ROGERS issued a national Class Action lawsuit on behalf of Canadians with Parkinson's disease and/or other medical conditions who allege to have developed compulsive behaviour such as pathological gambling, as a result of their use of the drug ReQuip, a dopamine agonist. The Class Action claim seeks millions of dollars in compensation from the Canadian drug manufacturer, GlaxoSmithKline Inc.
 
The representative plaintiff, Mr. Octavian Grosu from Brampton, Ontario, gambled compulsively while taking ReQuip and lost more than $250,000. Many more Canadians are believed to have suffered a similar experience and ReQuip’s product monograph was changed in late 2008 to refer to a potential risk of impulse control symptoms including compulsive behavior such as pathological gambling and hypersexuality. Medical reports have linked dopamine agonists, such as ReQuip, to compulsive behaviour including compulsive gambling.

If you would like to notify Health Canada of side effects you have experienced as a result of the use of ReQuip, please call the Health Canada Adverse Reaction Reporting Centre at their tollfree number, 1-866-234-2345.

This Class Action has not yet been certified.

If you’d like to learn more about this class action, please contact Darcy Merkur via e-mail or through our toll-free number 1-888-223-0448. Locally, in the Toronto area, you may call 416-868-3176.
 

Related Documents: 


By submitting this form, you accept the Mollom privacy policy.